Mobile Site ›
Print Friendly View

Test ID: BCRAB    
BCR/ABL, p210, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Quantitative, Monitoring Chronic Myelogenous Leukemia (CML)

‹ Back to Hematology index

NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Useful For Suggests clinical disorders or settings where the test may be helpful

Monitoring response to therapy in patients with chronic myeloid leukemia who are known to have the e13/a2 or e14/a2 fusion forms

Testing Algorithm Delineates situation(s) when tests are added to the initial order. This includes reflex and additional tests.

 

Special Instructions and Forms Describes specimen collection and preparation information, test algorithms, and other information pertinent to test. Also includes pertinent information and consent forms to be used when requesting a particular test

Method Name A short description of the method used to perform the test

Quantitative Reverse Transcription-Polymerase Chain Reaction (RT-PCR) using GeneXpert (Cepheid)
(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)

Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name

BCR/ABL, p210, Quant, Monitor

Aliases Lists additional common names for a test, as an aid in searching

Chronic Myelogenous Leukemia (CML)
CML (Chronic Myelogenous Leukemia)
CML RT-PCR
Philadelphia Chromosome Ph1 Bone Marrow/Blood